Financings Roundup

September 2008
BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5
The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold 900,000 common shares at $1.15 per share and five-year warrants to purchase 675,000 common shares at an exercise price of $1.90 per share.


Related Articles

  • Financings Roundup.  // BioWorld Today;10/13/2010, Vol. 21 Issue 198, p6 

    The article reports that Pluristem Therapeutics Inc. have signed definitive agreements with selected institutional and private investors to sell restricted common stock and warrants to raise 5.25 million U.S. dollars.

  • Financings Roundup.  // BioWorld Today;2/2/2009, Vol. 20 Issue 20, p7 

    The article reports that New York City-based Pluristem Therapeutics Inc. is raising $1.2 million through the sale of 1.03 million units. The offering consists of one restricted share of common stock priced at $1.16 and one five-year warrant to purchase a common share for $1.90. Pluristem is a...

  • Pluristem's PLX-PAD Plans Boosted by $36M Offering. Boggs, Jennifer // BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1 

    The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each,...

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld International;5/5/2010, Vol. 15 Issue 18, p5 

    The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II...

  • FDA Clinical Hold on PLX Safety Study Trips Pluristem. Powers, Marie // BioWorld Today;6/5/2013, Vol. 24 Issue 107, p1 

    The article reports on the 14.4% decrease in stocks of Pluristem Therapeutics Inc. amid the decision of the U.S. Food and Drug Administration (FDA) to stop the U.S. Phase II study of its Placental expanded cell therapy. Zami Aberman, chairman and chief executive officer of the biotechnology...

  • Financings Roundup.  // BioWorld Today;9/29/2009, Vol. 20 Issue 187, p10 

    The article reports on 250,620 U.S. dollars in gross proceeds raised by Kane Biotech Inc. through an early exercise warrant incentive program. The Winnipeg, Manitoba-based company is a developer of products targeting microbial matrices.

  • Vascular device maker Neovasc raises $1.4M in warrants exercise.  // Medical Device Daily;4/27/2010, Vol. 14 Issue 80, p4 

    The article reports that Neovasc, a vascular device maker based in Vancouver, British Columbia, has raised 1.4 million U.S. dollars after 4,635,114 warrants were exercised.

  • Financings Roundup.  // BioWorld Today;6/9/2010, Vol. 21 Issue 110, p5 

    The article focuses on the 2.5 million U.S. dollars raised by NeoStem Inc. from option and warrant exercises and an equity financing facility drawdown.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics